<DOC>
	<DOCNO>NCT02799602</DOCNO>
	<brief_summary>The purpose study assess efficacy safety BAY1841788 ( ODM-201 ) combination standard androgen deprivation therapy ( ADT ) docetaxel patient metastatic hormone sensitive prostate cancer .</brief_summary>
	<brief_title>ODM-201 Addition Standard ADT Docetaxel Metastatic Castration Sensitive Prostate Cancer</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter phase III study . The study population consist approximately 1300 subject metastatic hormone sensitive prostate cancer ( mHSPC ) , randomize ( 1:1 ratio ) receive either ODM-201 600 mg ( 2 x 300 mg tablet ) bid orally food placebo , addition standard androgen deprivation therapy ( ADT ) docetaxel . Subjects stratify randomization extent disease Alkaline Phosphatase level . All subject treat ADT standard therapy . Six cycle docetaxel administer randomization . The subject consider inclusion study metastatic prostate cancer candidate ADT docetaxel . Treatment ODM-201/placebo administer symptomatic progressive disease , change antineoplastic therapy , unacceptable toxicity , subject withdraws consent , withdrawal study discretion Investigator his/her designate associate ( ) , death , non-compliance , Sponsor terminate study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Metastatic disease Candidates ADT docetaxel . Started ADT without first generation anti androgen , longer 12 week randomization An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver renal function Prior treatment : LHRH agonist/antagonists ; second generation androgen receptor ( AR ) inhibitor enzalutamide , ARN509 , ODM201 ; investigational AR inhibitor ; CYP17 enzyme inhibitor abiraterone acetate oral ketoconazole antineoplastic treatment prostate cancer , chemotherapy immunotherapy prostate cancer prior randomization . Treatment radiotherapy/radiopharmaceuticals within 2 week randomization . Had follow within 6 month randomization : stroke , myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , congestive heart failure ( New York Heart Association Class III IV ) Had prior malignancy . Adequately treat basal cell squamous cell carcinoma skin superficial bladder cancer spread behind connective tissue layer ( i.e. , pTis , pTa , pT1 ) allow , well cancer treatment complete 5 year randomization subject diseasefree Gastrointestinal disorder procedure expect interfere significantly absorption study treatment . Inability swallow oral medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic hormone sensitive prostate cancer</keyword>
</DOC>